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The 2005 Disease Management Colloquium a 
Success 
 
The 2005 Disease Management Colloquium was held at Jefferson Medical College in 
Philadelphia on June 21-24, 2005. 
The Colloquium’s goal is to better educate government agencies, the healthcare 
industry, employers, and the general public about the important role disease 
management programs play in improving healthcare quality and outcomes for 
persons subject to chronic conditions. The following are highlights from a number of 
the morning keynote presentations. 
Is There Long-term Value in Disease Management Programs?  
Reflection on the 2004 CBO Report  
 
Paul Wallace, MD  
Executive Director, Care Management Institute, Kaiser Permanente  
 
In 2004, the Congressional Budget Office (CBO) was charged with assessing whether 
disease management programs could “pay for themselves.” The CBO concluded, 
“There is insufficient evidence to conclude that disease management programs can 
generally reduce overall health spending,” but also noted “such programs could be 
worthwhile even if they did not reduce costs.”1
How does one define the value of disease management programs? The answer will 
vary from stakeholder to stakeholder. “Value” is relative and subjective. Purchasers 
may define value by disease management’s affordability, consumers by the care 
experience, and clinicians by the clinical quality; all will assess programs in terms of 
return on investment and cost-effectiveness.  
 
Will disease management’s goal of “mass customization” be met with a return on 
investment? Increasing numbers of consumers are diagnosed with chronic 
conditions, and simply “harvesting” the returns may lead to price relief or 
shareholder return in the short run. But only with the re-investment of these savings 
can disease management companies and each stakeholder group reap the rewards 
and recognize the “value” of these programs.  
 
Is there long-term value in disease management programs?  




1. CBO. An Analysis of the Literature on Disease Management Programs. October 
13, 2004. Available at: www.cbo.gov/showdoc  
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The Impact of Information Technology on Disease Management 
 
Jeremy Nobel, MD, MPH  
 
Faculty, Department of Health Policy and Management  
Harvard School of Public Health  
 
Information technology (IT) has a major role to play not only in health care, but in 
disease management (DM). Traditional DM programs have created communication 
“silos,” preventing optimal integration of care across stakeholders - DM companies, 
providers, payers, and consumers. Existing DM programs are faced with other 
barriers to delivering services, including standardized care vs. customized care (mass 
customization), person-to-person connectivity without IT (distance and time factors), 
and the high tech vs. high touch conflict.  
 
Emerging healthcare IT has already begun to erode existing barriers and promote 
improved quality of care through such means as Web-based personal health records 
(PHR), home-based biometric devices (e.g., blood pressure cuffs that can send 
results directly to the PHR or the provider’s electronic medical record system), and 
constant (24/7) connectivity to the care team. These advances promise to improve 
the exchange of key health information between patients, DM organizations, and 
providers. They can identify intervention opportunities that may have been missed 
without “real-time” feedback and communication. In the evolving world of healthcare 
consumerism, these technologies encourage more involvement by patients in their 
care.  
 
Most Web-based health IT companies recognize that seamless transition to these 
tools and services has not and will not occur.  
 
Factors that may impede full implementation include consumer receptivity, 
interoperability of various data sources, provider adoption and utilization, and return 
on investment. Yet, there is great optimism that IT can flourish in health care and 
further DM’s quest for improved health outcomes.  
 
* * * * *
Disease Management National Policy Issues  
 
Christobel E. Selecky  
 
President, Disease Management Association of America  
Chief Executive Officer, Lifemasters  
 
Many policy issues impact the implementation of disease management (DM) within 
the current healthcare system. Cost concerns, demographic factors, societal changes 
and delivery systems, are key obstacles for all involved. Of particular interest to the 
DM industry is the underuse of evidence-based therapies for chronic conditions.  
 
The major goals of DM are to close the gaps in access to chronic care and to support 
the control of rising healthcare costs associated with those chronic diseases. The 
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Disease Management Association of America proposes to achieve this by introducing 
individual interventions at a population level through the use of evidence-based care 
plans and continuous patient monitoring.  
 
Looking ahead, the DM industry must confront the challenge of using DM as a 
platform to reduce underuse or misuse of medical services, and address the issue of 
how DM can work in a consumer-directed healthcare system. The mandate is clear - 
to avoid the fate of previous medical management efforts by ensuring that, “when 
we grow, we grow responsibly.”  
 
